These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32819746)

  • 21. [Behçet's disease].
    Brand HS; van Beusichem FF; van Nieuw Amerongen A
    Ned Tijdschr Tandheelkd; 2008 Jun; 115(6):340-5. PubMed ID: 18618988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unmet need in Behcet's disease: most patients in routine follow-up continue to have oral ulcers.
    Alibaz-Oner F; Mumcu G; Kubilay Z; Ozen G; Celik G; Karadeniz A; Can M; Oner SY; Inanc N; Atagunduz P; Ergun T; Direskeneli H
    Clin Rheumatol; 2014 Dec; 33(12):1773-6. PubMed ID: 24737283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of minimal clinically important improvement by using Oral Health Impact Profile-14 in Behçet's disease.
    Hayran O; Mumcu G; Inanc N; Ergun T; Direskeneli H
    Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S79-84. PubMed ID: 19796539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical presentations of Behçet's disease among Nigerians: a 4-year prospective study.
    Ajose FO; Adelowo O; Oderinlo O
    Int J Dermatol; 2015 Aug; 54(8):889-97. PubMed ID: 25494839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural history of Behçet's disease focusing on remission of oral ulcers.
    Tomizuka T; Kikuchi H; Okubo M; Asako K; Miyata S; Kono H
    Mod Rheumatol; 2023 Apr; 33(3):566-573. PubMed ID: 35445275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.
    Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH
    Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Outcome of Ustekinumab Therapy for Behçet's Disease.
    Mirouse A; Barete S; Desbois AC; Comarmond C; Sène D; Domont F; Bodaghi B; Ferfar Y; Cacoub P; Saadoun D;
    Arthritis Rheumatol; 2019 Oct; 71(10):1727-1732. PubMed ID: 31008548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of association between serum IL-9 levels and Behçet's disease.
    Nouri-Vaskeh M; Malek Mahdavi A; Khabbazi A; Jadideslam G
    Immunol Lett; 2019 Jul; 211():23-27. PubMed ID: 31095970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Six cases with Behcet's disease presenting cervical ulcer].
    Huang QS; Chen J; Hou XH; Wang LD; Liu Y
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):112-5. PubMed ID: 19570421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life and life satisfaction in patients with Behçet's disease: relationship with disease activity.
    Bodur H; Borman P; Ozdemir Y; Atan C; Kural G
    Clin Rheumatol; 2006 May; 25(3):329-33. PubMed ID: 16267609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Refractory Behçet's disease treated with low-dose interleukin-2: A case report.
    Zhou W; Liu T; Xiao X; He J
    Medicine (Baltimore); 2022 Oct; 101(42):e31173. PubMed ID: 36281176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of apremilast and its impact on serum cytokine levels in patients with Behçet's disease.
    Wakiya R; Ushio Y; Ueeda K; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
    Dermatol Ther; 2022 Aug; 35(8):e15616. PubMed ID: 35668044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of treatment adherence in patients with Behçet's disease: its relation to disease manifestations, patients' beliefs about medications, and quality of life.
    Zayed HS; Medhat BM; Seif EM
    Clin Rheumatol; 2019 Mar; 38(3):761-768. PubMed ID: 30367312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
    Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behçet's disease.
    Lee JH; Jung JY; Bang D
    J Eur Acad Dermatol Venereol; 2008 May; 22(5):590-5. PubMed ID: 18093111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prevalence of Behçet's disease in a city in Central Anatolia in Turkey.
    Çölgeçen E; Özyurt K; Ferahbaş A; Borlu M; Kulluk P; Öztürk A; Öner AÖ; Gün İ; Aşçıoğlu Ö
    Int J Dermatol; 2015 Mar; 54(3):286-9. PubMed ID: 25039755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salivary levels of HNP 1-3 are related to oral ulcer activity in Behçet's disease.
    Mumcu G; Cimilli H; Karacayli Ü; Inanc N; Türe-Özdemir F; Eksioglu-Demiralp E; Ergun T; Direskeneli H
    Int J Dermatol; 2013 Oct; 52(10):1198-201. PubMed ID: 22861387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behçet's disease.
    Yesudian PD; Edirisinghe DN; O'Mahony C
    Int J STD AIDS; 2007 Apr; 18(4):221-7. PubMed ID: 17509169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study.
    Matsuda T; Ohno S; Hirohata S; Miyanaga Y; Ujihara H; Inaba G; Nakamura S; Tanaka S; Kogure M; Mizushima Y
    Drugs R D; 2003; 4(1):19-28. PubMed ID: 12568631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-cultural adaptation and validation of the Behcet's Disease Current Activity Form in Korea.
    Choi HJ; Seo MR; Ryu HJ; Baek HJ
    Korean J Intern Med; 2015 Sep; 30(5):714-8. PubMed ID: 26354066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.